The strategic acquisitions expand the company’s structural heart disease technologies.
The resignation will be effective in about a month, according to reports.
Despite pricing pressures, several sectors within the medical device industry can expect to enjoy growth and attract attention from investors.
Technologically superior devices, favorable research outcomes and a supportive regulatory structure are fueling growth.
The deal will help J&J speed up its entry into the robotics market.
The deal will help strengthen the Edwards portfolio of smart monitoring technologies.
A recent paper released by Duke University cites the promise of AI, but urges policy changes in order to bring AI-enabled clinical decision software to fruition.
The disgraced former CEO once oozed total confidence about her company and product, and in latest released footage says “I don’t know” more than 600 times during a 2017 deposition.
The challenges will continue to keep medtech manufacturers and other stakeholders in the healthcare industry on their toes.
The companies are finally putting to bed all outstanding patent disputes.